Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Considering that, Diacerein is on the market for 16 years being used continuously in elderly
patients with osteoarthritis without experience significant side effects, and considering the
anti-hyperglycemic effect and the improvement in the insulin resistance observed in animal
models of type 2 diabetes treated with this medicine.
The aim of this study is to investigate the effect of Diacerein, a medication with
anti-osteoarthritic properties and moderately analgesic activity, anti-inflammatory and
antipyretic, which demonstrates inhibit properties for the synthesis of pro-inflammatory
cytokines such as interleukin 1 (IL-1). Administered for 12 weeks and the effect in the
glycemic and metabolic control in patients with diabetes mellitus 2 and secondary failure to
metformin treatment.
Phase:
Phase 2
Details
Lead Sponsor:
ANS Pharma
Collaborators:
Conselho Nacional de Desenvolvimento Científico e Tecnológico University of Campinas, Brazil